Omega Diagnostics, the medical diagnostics, increased its revenue by 4% to £7.11m in the six months ended 30 September.
Food Intolerance revenue increased by 8% to £4.13m and Food Detective grew by 2% to £0.95m.
Allergy/Autoimmune revenue declined by 5% to £1.67m. In Germany, revenue declined by 9% in Euro terms but was mitigated by a favourable currency impact so that in reported terms revenue was down by 2% to £1.43m. Autoimmune sales decreased to £0.24m from £0.30m in the prior period.
Infectious Disease sales increased by 7% to £1.31m (2016: £1.23m) with gains in Asia and the Middle East mitigating a reduction in Africa.
Gross profit was marginally ahead of the prior period at £4.49m (2016: £4.47m) meaning gross margin reduced by 2.4 percentage points to 63.1%. Of this reduction in margin, 1.6 percentage points related to an increase in material costs with the balance relating to an increase in labour costs.
Adjusted profit before tax reduced to £0.22m compared to £0.56m in the prior period, reflecting investment in salary increases and sales promotion activities.
David Evans, chairman, said: "Overall, we remain confident about our long term prospects. Whilst we are experiencing a number of short term headwinds in our core business, we believe that the impact will be more than mitigated by the success we expect from positive achievements over the medium term as we complete the commercialisation of key products for Allergy, Malaria and now CD4."
At 9:03am: (LON:ODX) Omega Diagnostics Group PLC share price was -3.38p at 16.88p